Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Gamida Cell Ltd. engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The firm offers Omidubicel, an investigational product with potential as a life-saving alternative for patients in need of a bone marrow transplant, and a line of modified and unmodified nicotinamide-enabled natural killer cells targeted at solid tumor and hematological malignancies. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Boston, MA.
The company released data from a late-stage clinical trial.
Early data for this company's natural killer cells is drawing lots of attention.
GMDA earnings call for the period ending June 30, 2022.
GMDA earnings call for the period ending March 31, 2022.
GMDA earnings call for the period ending December 31, 2021.
GMDA earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.